STAT

AUGUST 1, 2023

The U.S. Department of Labor claims in a new lawsuit that a UnitedHealth Group unit illegally rejected emergency room care and urine drug screen claims for thousands of people. UMR, Inc., a Wisconsin-based third-party administrator owned by UnitedHealth, manages benefits for more than 2,100 employee health plans. The federal government says the company denied ER visits and urine drug screens for years using a process that didn’t meet federal standards for health plans that employers fund

Hospitals 246

Hospitals 246

PharmaVoice

AUGUST 1, 2023

Afaxys is a self-described "socially conscious" contraceptive healthcare company serving an unusual demographic for pharma: the public health sector.

130

130

STAT

AUGUST 1, 2023

For what would have been Henrietta Lacks’s 103th birthday, her family got her some justice: A settlement with Thermo Fisher Scientific over the Massachusetts-based company’s use of cells obtained without her consent seven decades ago. The story of Lacks, a Black woman whose cells have contributed to scientific breakthroughs ranging from the development of polio and cancer treatments to the mapping of the human genome, is one of the best-known tales of the exploitation of marginaliz

246

246

PharmaVoice

AUGUST 1, 2023

Much like the year she first graced store shelves, Barbie has taken over the world. But now, the women's health landscape looks a whole lot different.

130

130

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

AUGUST 1, 2023

Harrison has an informal test that he runs on primary care physicians when he meets them for the first time: the eye contact test. When he arrives at the appointment and tells them that he’s transgender, he watches their eyes for a reaction. He’s looking for signs of shock — have they ever met a trans person before? Do they get nervous, or start talking at him, rather than with him?

236

236

Pharmaceutical Business Review

AUGUST 1, 2023

The drug-device combination product, Breyna is claimed to be the first US Food and Drug Administration (FDA)-approved generic version of AstraZeneca’s Symbicort. It will be immediately available in 160 mcg/4.5 mcg and 80 mcg/4.5 mcg doses. The therapy is indicated for the treatment of asthma patients aged six years and above. It is also indicated as the maintenance treatment of airflow obstruction and to reduce exacerbations in COPD patients, including chronic bronchitis and/or emphysema.

98

98

PharmaTech

AUGUST 1, 2023

AstraZeneca, via its subsidiary Alexion Pharmaceuticals, will purchase a portfolio of preclinical rare disease gene therapies from Pfizer in a deal worth up to $1 billion.

96

96

STAT

AUGUST 1, 2023

Three large and growing physician groups backed by the private equity giant Welsh, Carson, Anderson & Stowe have hired a prominent lobbying firm to influence federal policy covering mergers and acquisitions. Over the past two weeks, United Musculoskeletal Partners, U.S. Anesthesia Partners, and U.S. Radiology Specialists each registered with Forbes Tate Partners, a lobbying shop founded by political insiders who used to work in President Bill Clinton’s administration.

Hospitals 231

Hospitals 231

Express Pharma

AUGUST 1, 2023

The loss of exclusivity of AbbVie’s Humira (adalimumab) has become a perfect scenario to test if the Biologics Price Competition and Innovation (BPCI) act in the US can achieve the intention of the law. The potential revenue replacing Humira has resulted in many adalimumab biosimilar offerings being brought forth (currently nine FDA-approved agents), and a rapidly overcrowded market.

Biosimilars 95

Biosimilars 95

STAT

AUGUST 1, 2023

I was in seat 20C on a flight home this March, when I felt my throat closing. Minutes earlier, hives had appeared on my face and chest. As a physician, I knew exactly what these symptoms meant: anaphylaxis, a severe allergic reaction so precipitously fatal that putting a breathing tube down someone’s throat is sometimes necessary. What I needed was an epinephrine autoinjector, also known as an EpiPen, but neither the airplane emergency medical kit nor any other passenger had one.

227

227

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

The Pharmacist

AUGUST 1, 2023

Responsible pharmacists should be allowed to delegate aspects of the preparation, assembly, sale and supply of medicines to appropriate members of the pharmacy team in defined circumstances, a cross-sector group reviewing pharmacy supervision has suggested. And they proposed that legislation be amended to allow the preparation and assembly of medicines to take place outside of […] The post Allow delegation and out-of-hours assembly, suggests pharmacy supervision group appeared first on The

93

93

STAT

AUGUST 1, 2023

For almost 44 years, Willie Bell never missed his appointment to check for prostate cancer. But then the pandemic hit. The doctor’s office was closed. Three months passed before he was able to be screened in January 2021. “So the doctor kept putting it off and I call him and say, ‘listen I get my PSA level checked every year. I would hate for you to tell me that you backed me off for a year, then you find cancer, because I’ll be pissed off,’” said Bell,

226

226

The Pharmacist

AUGUST 1, 2023

The cross-sector pharmacy supervision group has agreed on the importance of having a pharmacist physically present in a community pharmacy, however it was unable to reach a consensus about whether this should be embedded in primary legislation or specified elsewhere. It published a full report outlining its process and conclusions today, including suggesting that ‘supervision’ […] The post Supervision: The debate around ‘physical presence’ in legislation appeared first on The Pharmacist.

Community Pharmacies 92

Community Pharmacies 92

STAT

AUGUST 1, 2023

Last November, an employee at Intas Pharmaceuticals, which makes several widely used chemotherapies that are in short supply, was seen pouring acetic acid in a trash bin containing documents at a manufacturing facility. Another employee failed to report all test results on product samples and, at times, printouts were tossed in the trash. Plastic bags filled with torn and discarded important production records were stashed under a stairwell and on a truck parked outside.

Chemotherapy 226

Chemotherapy Documentation 226

The Pharmacist

AUGUST 1, 2023

A cross-sector working group has set out proposed changes to supervision legislation and guidance, to enable the pharmacy workforce to maximise their skills and professional roles, to promote integration within the wider NHS, and to free up pharmacists to be available for patients and to deliver clinical services. The group included representatives from the Association […] The post What changes are being proposed to supervision legislation and guidance?

88

88

STAT

AUGUST 1, 2023

WASHINGTON – The cannabis industry is dramatically scaling back its presence in Washington. Curaleaf, one the largest cannabis companies in the world, spent nearly 40% less on lobbying in the first half of 2023 than it did at its peak in 2019. Others like Columbia Care and Pax Labs got rid of their entire lobbying teams. Of the four major cannabis industry coalitions that have been pushing for federal legalization of marijuana the longest, one has seen its revenue cut in half; two others

226

226

Outsourcing Pharma

AUGUST 1, 2023

The National Health Service (NHS) research ethics committee has approved a non-cancer chronic pain clinical trial being rolled out by private health clinic LVL Health.

98

98

STAT

AUGUST 1, 2023

Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like a pleasant morning to lift the spirits. A cool breeze and warm sun are enveloping the Pharmalot campus as we hunker down and sift through our ever-growing to-do list. A familiar exercise, yes? Well, time to get cracking. So please join us for a daily ritual — a few cups of stimulation.

Drug Pricing 225

Drug Pricing 225

Pharma Times

AUGUST 1, 2023

The approval involves the roll-out of a non-cancer chronic pain study for up to 5,000 patients - News - PharmaTimes

104

104

STAT

AUGUST 1, 2023

The airline industry is often held up as a model of operational excellence — one that the health care industry would do well to emulate. This summer, however, I was surprised to find myself in circumstances in which the reverse seemed true. Like thousands of travelers across the nation, I spent several days in July stranded in an airport with multiple canceled flights, lost luggage, and a whole lot of uncertainty about what to do with my hotel reservations.

Customer Service 221

Customer Service Hospitals 221

Outsourcing Pharma

AUGUST 1, 2023

The National Health Service (NHS) research ethics committee has approved a non-cancer chronic pain clinical trial being rolled out by private health clinic LVL Health.

98

98

STAT

AUGUST 1, 2023

EQRx is done, sold for its cash. The once-buzzy  but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday. The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

219

219

pharmaphorum

AUGUST 1, 2023

In this episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with André Deschamps, formerly president of Europa Uomo, the voice of men with prostate cancer in Europe. Deschamps is now involved in the Let’s Talk Prostate Cancer (LTPC) Expert Group, as well as the Belgian society, Wij Ook (part of Europa Uomo).

85

85

STAT

AUGUST 1, 2023

This story is the first in a series of profiles of influential figures and decision-makers in health tech. S AN FRANCISCO — For Surbhi Sarna, the first and only health care partner at Y Combinator, opening her inbox every morning is like drinking from a firehose. There are the dozens of companies wanting to capitalize on the momentum around large language models.

Hospitals 202

Hospitals 202

ID Stewardship

AUGUST 1, 2023

In this article, a pharmacist from Turkey with advanced training in the area of infectious diseases provides insights on antimicrobial stewardship in Turkey. Interview with: Emre Kara, MSc., Ph.D. Interviewer: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP Article Posted 1 August 2023 A man colonized with extensively drug resistant Acinetobacter baumannii gets on a plane.

Hospitals 84

Hospitals Community Pharmacies Dosage Communication 84

STAT

AUGUST 1, 2023

On Tuesday, Duke Health and Microsoft announced a five-year partnership that will support artificial intelligence applications in medicine, with a focus on building out infrastructure such as cloud-based data platforms. Duke Health and Microsoft are both members of the Coalition for Health AI , a group of companies, hospitals, and federal agencies that formed late last year to develop guidelines for the responsible use of AI in medicine.

Hospitals 200

Hospitals 200

Outsourcing Pharma

AUGUST 1, 2023

PureTech Health plc has been awarded $11.4 million (Â8.9 million) from the US Department of Defense (DoD) to advance its therapeutic candidate for the potential treatment of neurological and neuropsychiatric disorders.

98

98

STAT

AUGUST 1, 2023

As Verily aims to get on track, the Alphabet life science company has hired Andrew Trister, an oncologist and veteran of big technology companies and research, as its new chief scientific officer. Trister will lead Verily’s population health initiatives, including public health solutions like the company’s ongoing work to combat disease-carrying mosquito populations and a program that helps wastewater treatment plants monitor for pathogens.

198

198

Pharmaceutical Technology

AUGUST 1, 2023

BioNTech has acquired all the remaining shares of technology company InstaDeep in a deal valued at €500m ($549m) in cash.

98

98

Pharma Times

AUGUST 1, 2023

First-in-human study to be undertaken at the Manchester University Hospitals NHS Foundation Trust - News - PharmaTimes

Hospitals 92

Hospitals 92

Express Pharma

AUGUST 1, 2023

Lupin announced that its wholly-owned subsidiary, Novel Laboratories, based in Somerset, New Jersey, has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil), a generic equivalent of Derma-Smoothe/FS Topical Oil, 0.01% (Scalp Oil), of Hill Dermaceuticals, Inc.

78

78

Drug Channels

AUGUST 1, 2023

In my most recent video webinar , I explored how plans and PBMs are turning to novel—and highly controversial—benefit design tools that access manufacturers’ patient support spending: copay accumulators, maximizers, and alternative funding programs. In the video excerpt below, I describe these new approaches that plans offset specialty drug expenses.

76

76

World Pharma News

AUGUST 1, 2023

Disease modeling and target identification are critical and time-consuming portions of the drug discovery process and areas where artificial intelligence (AI) is already making a substantial impact.

68

68

pharmaphorum

AUGUST 1, 2023

How pharma can improve regulatory compliance with AI-based technology Mike.

94

94

PharmExec

AUGUST 1, 2023

New deal to focus on commercialization efforts in Latin America.

98

98